Low Expression of NQO1 Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients treated with TAC Regimen

Abstrakt

The aim of this study was to evaluate preoperative tumour expression of NAD(P)H: quinone oxidoreductase 1 (NQ01) along with other biological markers as potential predictors of pathological complete response (pCR) to neoadjuvant docetaxel, doxorubicin, and cyclophosphamide-containing (TAC) chemotherapy in patients with primary breast cancer.

Klíčová slova

• breast canceer
• neoadjuvant therapy
• predictive biomarkers